Actor Abbas, who is known among Tamil audiences for playing a romantic hero in such films as Kadhal Desam, Padayappa, and Minnale, among others, has been missing from the scene for close to a decade now.
He appeared in an interaction with a YouTube channel recently and opened up about several issues, including his struggle with suicidal thoughts as a teenager and why he decided to quit the film industry.
The actor, who is not very fond of social media, said, "I made an exception during the Covid period. While residing in New Zealand, I utilised Zoom calls to connect with fans. My intention was to assist those in need, particularly those struggling with thoughts of suicide. I could empathise with those feelings because I, too, have experienced them firsthand. During my teenage years, I went through a tumultuous period where I contemplated taking my own life after failing the 10th grade. The departure of my girlfriend at the time intensified those thoughts. However, something profound occurred that transformed me. While standing by the roadside, contemplating stepping in front of a speeding vehicle, I noticed a passing motorist and had a realisation: if I were to act on my impulses, that person’s life would also be profoundly affected. Even in my darkest moment, I found myself considering the well-being of another individual.”
He continued, “During childhood, I never held much interest in academics. I strongly believe that it is unfair to judge or assess someone solely based on their academic achievements, as people may possess alternative talents and strengths. It is crucial for us to recognise and nurture those talents. In general, men often struggle to open up and tend to keep their emotions suppressed, enduring silent suffering. I desired to address these issues by establishing a connection with my fans, encouraging them to share their feelings and experiences,” he added.
Opening up about his decision to leave the film industry, he said, “Following my initial achievements, some of my movies faced failure, leaving me financially destitute and unable to afford even basic necessities like rent or cigarettes. Initially, my pride prevented me from seeking alternative employment. However, I soon approached producer RB Choudary, requesting work. He offered me the opportunity to be part of the film Pooveli. However, I eventually left films because I got bored. I wasn’t enjoying my work. I distinctly recall advising my friends, who came to watch my Bollywood debut film Ansh: The Deadly Part not to waste their time as I considered it to be bakavas. In order to provide for my family, I worked as a bike mechanic and drove taxis in New Zealand.”
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.